Catalyst Pharmaceuticals, Inc.
CPRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. With a market capitalization of $3.82B, it sits in mid-cap territory. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.
Market Cap
$3.82B
Beta
0.72
P/E (TTM)
18.05
P/E (Fwd)
9.96
EPS (TTM)
$1.73
EPS (Fwd)
$3.14
ROE
24.5%
ROA
16.3%
Cash
$755.9M
Total Debt
$2.7M
Free CF
$171.8M
52W Change
25.4%
Annual Financials
Cash vs Debt
With $755.9M in cash and $2.7M in debt, CPRX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $171.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 24.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 16.3% further supports the picture of efficient asset utilization. Revenue has grown from $214.2M (2022) to $589.0M (2025), reflecting a 175% increase over the period.
With cash comfortably exceeding debt, CPRX has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CPRX.